Immunovant, Inc. (NASDAQ: IMVT) is a Healthcare company (Biotechnology) with a market capitalization of $6.8B. The Maz Rating grades it against the other companies in its sector.
Immunovant, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.80, Immunovant, Inc. trades at 970.7x sales and 10.5x book value. Over the last twelve months it generated about $7M of revenue and a net loss of $522M. It runs an operating margin of -7488.4% and a net margin of -7173.5%. It shows return on equity of -63.0%, return on invested capital of -80.7% and a free cash flow yield of -5.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.31. Over the past 52 weeks the share price ranged from $21.86 to $45.42, with a beta of 0.84.
Immunovant, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 18 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.